Regeneron to Buy 23andMe for $256M Amid Privacy Concerns

Regeneron Pharmaceuticals, a leading biotechnology company headquartered in Tarrytown, New York, has announced its successful bid to acquire substantially all assets of 23andMe Holding Co. for $256 million following a bankruptcy auction.

This acquisition includes 23andMe’s flagship Personal Genome Service® (PGS), Total Health and Research Services business lines, and its extensive Biobank, which houses genetic data from over 15 million customers collected via direct-to-consumer saliva testing kits.

The transaction, expected to close in the third quarter of 2025, is subject to bankruptcy court and regulatory approvals.

Regeneron’s leadership emphasized that this move will bolster its genetics-guided research and drug development capabilities.

The company has a proven track record in leveraging large-scale genomic data, having previously sequenced genetic information from nearly three million research participants and linked deidentified DNA sequences to electronic health records using proprietary analytics and machine learning technologies.

The integration of 23andMe’s dataset is expected to accelerate discoveries in areas such as ophthalmology, oncology, immunology, and infectious diseases.

Data Privacy, Security, and Ethical Oversight

According to the report, the acquisition has reignited public and regulatory scrutiny over the privacy and ethical use of genetic data, especially after a significant data breach at 23andMe in 2023 that compromised sensitive information of millions of users.

Lawmakers and consumer advocates have expressed concerns about the potential misuse of this vast trove of personal and genetic data.

In response, Regeneron has pledged to uphold the highest standards of data privacy and security. The company will adhere to 23andMe’s existing consumer privacy policies and all applicable data protection laws.

To further reassure stakeholders, Regeneron is prepared to cooperate with a court-appointed, independent Customer Privacy Ombudsman, who will review the company’s privacy programs and security controls before the transaction is finalized.

Additionally, 23andMe recently agreed to appoint an ombudsman to oversee user data protection, following pressure from state attorneys general.

Regeneron clarified that the acquisition does not include 23andMe’s telehealth subsidiary, Lemonaid Health, which will be discontinued as part of the restructuring.

All consumer genome services will continue uninterrupted, and the current team at 23andMe will be retained to maintain operational continuity.

Implications for Genomic Research and Personalized Medicine

This acquisition represents a significant shift in the landscape of consumer genomics and pharmaceutical innovation.

By combining Regeneron’s proprietary technologies—such as VelociSuite®, which enables the development of fully human antibodies and bispecific antibodies—with 23andMe’s vast genetic database, the company aims to drive breakthroughs in personalized medicine and drug discovery.

The Regeneron Genetics Center® (RGC), now further empowered by this acquisition, will continue to use advanced data analytics and machine learning to perform large-scale analyses, making meaningful associations between genes and diseases.

This integrated approach is expected to optimize clinical trials, validate research programs, and identify novel therapeutic targets at unprecedented speed and scale.

As 23andMe transitions to become a wholly owned subsidiary of Regeneron, the combined entity is poised to set new standards for ethical stewardship of genetic data and to advance the shared mission of improving human health and wellness through data-powered insights and innovative science.

Key Technical Terms and Codes:

• Personal Genome Service® (PGS): 23andMe’s core direct-to-consumer genetic testing offering.
• Biobank: A large-scale repository of biological samples and associated data.
• VelociSuite®: Regeneron’s proprietary technology platform for antibody discovery and development.
• Regeneron Genetics Center® (RGC): Regeneron’s genomic research initiative.
• Machine Learning: Used for large-scale genomic data analysis and gene-disease association studies.
• Chapter 11 Bankruptcy: Legal process under which 23andMe sought protection and reorganization.

Find this Story Interesting! Follow us on LinkedIn and X to Get More Instant updates

The post Regeneron to Buy 23andMe for $256M Amid Privacy Concerns appeared first on Cyber Security News.